Nitrogen-containing tricondensed ring PRMT5 inhibitor, method for producing the same, and pharmaceutical uses
Nitrogen-containing tricondensed ring PRMT5 inhibitors selectively target PRMT5 in MTAP-deficient tumor cells, addressing the challenge of side effects in normal tissues and enhancing treatment efficacy.
JP7873890B2Active Publication Date: 2026-06-15ABBISKO THERAPEUTICS CO LTD
5 Cites 0 Cited by
Patent Information
- Application Number
- JP2024569156
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-02-22
- Filing Date
- 2023-06-26
- Publication Date
- 2026-06-15
- Estimated Expiration
- 2043-06-26
AI Technical Summary
Technical Problem
Existing PRMT5 inhibitors are not selective enough to target MTAP-deficient tumor cells without affecting normal tissues, leading to significant side effects.
Method used
Development of nitrogen-containing tricondensed ring PRMT5 inhibitors that selectively target PRMT5 bound to MTA, which is enriched only in MTAP-deficient tumor cells, minimizing impact on normal cells.
Benefits of technology
The inhibitors exhibit strong inhibitory effects against PRMT5, providing a therapeutic window to treat diseases mediated by PRMT5 while minimizing side effects on normal tissues.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a nitrogen-containing tricyclic PRMT5 inhibitor, a method for producing the same, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure represented by formula (I), a method for producing the same, a drug composition containing the same, and its use as a PRMT5 inhibitor and its use in the treatment and / or prevention of diseases mediated by PRMT5. Here, each substituent of formula (I) is the same as defined in the specification. 【Chemical 1】 TIFF2025516926000204.tif44144
Need to check novelty before this filing date? Find Prior Art